Characterization of orbital masses by multiparametric MRI

Ro, Sa-Ra; Asbach, Patrick; Siebert, Eberhard; Bertelmann, Eckart; Hamm, Bernd; Erb-Eigner, Katharina

doi:10.1016/j.ejrad.2015.11.041

Cited by 69 publications

(60 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DCE MRI is a valuable part of the multiparametric orbital protocols for imaging evaluation of malignancy . The present study discovered significant differences in TIC parameters (T max , CI, ER, and WR) between the orbital lymphoma and orbital inflammation.…”

Section: Discussionsupporting

confidence: 49%

“…Advances in MRI techniques, such as diffusion‐weighted imaging (DWI) and dynamic contrast‐enhanced (DCE) MRI, have been used for preoperative diagnosis of space‐occupying lesions in the orbit . Haradome et al and Sepahdari et al studied the apparent diffusion coefficient (ADC) in order to distinguish lymphoma from inflammation in the orbit .…”

mentioning

confidence: 99%

“…Haradome et al and Sepahdari et al studied the apparent diffusion coefficient (ADC) in order to distinguish lymphoma from inflammation in the orbit . Furthermore, Ro et al reported that the combination of DWI and DCE MRI improved the diagnostic performance in distinguishing benign from malignant orbital lesions. Nevertheless, the effect of DCE MRI is unclear and the combination of DWI and DCE MRI remains to be elucidated in comparison of orbital lymphoma with orbital inflammation in previous studies.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Lymphoma and inflammation in the orbit: Diagnostic performance with diffusion‐weighted imaging and dynamic contrast‐enhanced MRI

Sun

Song

Wang

et al. 2016

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 49%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Lymphoma and inflammation in the orbit: Diagnostic performance with diffusion‐weighted imaging and dynamic contrast‐enhanced MRI

Sun

Song

Wang

et al. 2016

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…All three studies evaluating a pharmacokinetic model used a two‐compartment ET model with discordant results . Ro et al showed that the perfusion parameter K‐trans was significantly higher in malignant lesions, whereas no significant difference could be found in our study or the two other studies. They also showed that Ve was lower in malignant lesions without reaching significance, whereas our results and those of Hu et al showed a significant difference.…”

Section: Discussioncontrasting

confidence: 48%

“…There are a small number of studies in the literature regarding both DCE imaging of orbital lesions and comparison of pharmacokinetic models. Only a few DCE MRI studies have previously evaluated orbital lesions, and a majority of them used only model‐free analysis or an arbitrary chosen model to discriminate between benign and malignant lesions . All three studies evaluating a pharmacokinetic model used a two‐compartment ET model with discordant results .…”

Section: Discussionmentioning

confidence: 99%

Quality‐based pharmacokinetic model selection on DCE‐MRI for characterizing orbital lesions

Balvay

Cuénod

Marais

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background Although several studies have evaluated dynamic contrast‐enhanced (DCE) MRI in the orbit, showing its utility when detecting and diagnosing orbital lesions, none have evaluated the pharmacokinetic models. Purpose To provide a quality‐based pharmacokinetic model selection for characterizing orbital lesions using DCE‐MRI at 3.0T. Study Type Prospective. Population From December 2015 to April 2017, 151 patients with an orbital lesion underwent MRI prior to surgery, including a high temporal resolution DCE sequence, divided into one training and one test dataset with 100 and 51 patients, respectively. Field Strength/Sequence 3T/DCE. Assessment Six different pharmacokinetic models were tested. Statistical Tests Univariate and multivariate analyses were performed using Wilcoxon‐2‐sample tests and a logistic regression to compare parameters between malignant and benign tumors for each pharmacokinetic model for the whole cohort. Receiver operating characteristic (ROC) curve analyses were performed on the training dataset to determine area under curve (AUC) and optimal cutoff values for each pharmacokinetic model, then validated on the test dataset to calculate sensitivity, specificity, and accuracy. Results Regardless of the model, tissue blood flow and tissue blood volume values were significantly higher in malignant vs. benign lesions: 103.8–195.1 vs. 65–113.8, P [<10‐4–2.10‐4] and 21.3–36.9 vs. 15.6–33.6, P [<10‐4–0.03] respectively. Extracellular volume fraction and permeability–surface area product or transfer constant appeared to be less relevant: 17.3–27.5 vs. 22.8–28.2, P [0.01–0.7], 1.7–4.9, P [0.2–0.9] and 9.5–38.8 vs. 8.1–22.8, P [<10‐4–0.6], respectively. ROC curves showed no significant differences in AUC between the different models. The two‐compartment exchange (2CX) model ranked first for quality. Data Conclusion DCE MRI pharmacokinetic model‐derived parameters appeared to be useful for discriminating benign from malignant orbital lesions. The 2CX model provided the best quality of modeling and should be recommended. Perfusion‐related DCE parameters appeared to be significantly more relevant to the diagnostic process. Level of Evidence 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:1514–1525.

show abstract

Benign and malignant orbital lymphoproliferative disorders: Differentiating using multiparametric MRI at 3.0T

et al. 2016

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

show abstract

Characterization of orbital masses by multiparametric MRI

Cited by 69 publications

References 21 publications

Lymphoma and inflammation in the orbit: Diagnostic performance with diffusion‐weighted imaging and dynamic contrast‐enhanced MRI

Lymphoma and inflammation in the orbit: Diagnostic performance with diffusion‐weighted imaging and dynamic contrast‐enhanced MRI

Quality‐based pharmacokinetic model selection on DCE‐MRI for characterizing orbital lesions

Benign and malignant orbital lymphoproliferative disorders: Differentiating using multiparametric MRI at 3.0T

Contact Info

Product

Resources

About